弘前大学医学部附属病院は、青森県弘前市にある病院である。特定機能病院。 2015年8月26日に原子力災害時の被曝医療の中心になる「高度被ばく医療支援センター」に指定された。

During the past decade, Hirosaki University School of Medicine & Hospital conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hirosaki University School of Medicine & Hospital" #1 sponsor was "Pfizer" with 4 trials, followed by "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 4 trials sponsored, "Japan Clinical Cancer Research Organization" with 2 trials sponsored, "Aichi Cancer Center" with 1 trials sponsored and "Gynecologic Oncology Trial & Investigation Consortium" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hirosaki University School of Medicine & Hospital" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Japan Clinical Oncology Group" with 1 trials as a collaborator and "Japanese Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Hirosaki University School of Medicine & Hospital" are "Colorectal Cancer" (2 trials), "Epithelial Ovarian Cancer" (2 trials), "Gastric Cancer" (2 trials), "Gastrointestinal Stromal Tumor" (2 trials) and "Metastatic Cancer" (2 trials). Many other conditions were trialed in "Hirosaki University School of Medicine & Hospital" in a lesser frequency.

Most popular intervention types in "Hirosaki University School of Medicine & Hospital" are "Drug" (13 trials), "Device" (2 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "UFT adjuvant chemotherapy" (2 trials), "Avelumab" (1 trials), "Avelumab (MSB0010718C)" (1 trials), "Axitinib (AG-013736)" (1 trials) and "Best Supportive Care" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hirosaki University School of Medicine & Hospital" are 13 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hirosaki University School of Medicine & Hospital". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Hirosaki University School of Medicine & Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hirosaki University School of Medicine & Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".